Lack of relationship between 25-hydoxyvitamin D concentration and a titer of antibodies to hepatitis B surface antigen in children under 12 years of age.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 25 09 2021
accepted: 27 10 2022
entrez: 10 11 2022
pubmed: 11 11 2022
medline: 15 11 2022
Statut: epublish

Résumé

The effect of vitamin D levels on the response to the hepatitis B vaccine in childhood and the induced levels of antibodies against the hepatitis B surface antigen (anti-HBs) is not yet well understood. The study aimed to investigate the relationship between age, serum 25-hydroxyvitamin D (25(OH)D) concentration and anti-HBs titer among children under 12 years old. Serum 25(OH)D concentration and anti-HBs titer were determined in 352 healthy Caucasian children with the average age of 4.2 (2.5; 6.3) years. All children were vaccinated with 3 doses of hepatitis B vaccine (Engerix-B, GlaxoSmithKline Pharmaceuticals Limited) in infancy according to the Centers for Disease Control and Prevention recommendations. Only 14.5% of children had an optimal concentration of 25(OH)D ≥ 30 ng/mL and 71.9% children had a seroprotective anti-HBs titer ≥ 10 mIU/mL. Significant negative correlations were found between 25(OH)D, anti-HBs titer and age (r = -0.420, p = 0.000; r = -0.425, p = 0.000, respectively), and a weak positive correlation between 25(OH)D concentration and anti-HBs titer (r = 0.243, p = 0.000). Analysis of six clusters of children demonstrated that age is the main factor affecting anti-HBs titer. One third of children under 12 years of age had nonprotective anti-HBs titer < 10 mIU/mL and around 40% had vitamin D deficiency. We conclude that vitamin D status has no impact on anti-HBs titer in children vaccinated against hepatitis B virus in infancy. Age, so time since the receipt of the last dose of hepatitis B vaccine, is the main factor influencing a decline in anti-HBs titer.

Identifiants

pubmed: 36355809
doi: 10.1371/journal.pone.0277473
pii: PONE-D-21-30962
pmc: PMC9648759
doi:

Substances chimiques

Hepatitis B Vaccines 0
Hepatitis B Surface Antigens 0
Hepatitis B Antibodies 0
Vitamins 0
Vitamin D 1406-16-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0277473

Informations de copyright

Copyright: © 2022 Dabrowska-Leonik et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Vaccine. 2008 Jan 30;26(5):601-13
pubmed: 18178294
Sci Rep. 2018 Aug 22;8(1):12550
pubmed: 30135554
PLoS One. 2016 Dec 15;11(12):e0168640
pubmed: 27977797
Vox Sang. 2010 Jul 1;99(1):77-84
pubmed: 20202182
PLoS One. 2015 Dec 30;10(12):e0145209
pubmed: 26716979
Eur J Pediatr. 1985 Jul;144(2):160-3
pubmed: 4043127
Expert Rev Vaccines. 2014 Nov;13(11):1395-403
pubmed: 25245883
Am J Med. 1989 Sep 4;87(3A):36S-40S
pubmed: 2528297
J Infect Dis. 2006 Feb 15;193(4):598-600
pubmed: 16425140
Infect Immun. 1996 Apr;64(4):1100-9
pubmed: 8606065
Expert Rev Vaccines. 2015;14(11):1427-40
pubmed: 26325349
Steroids. 1987 Jan-Mar;49(1-3):55-72
pubmed: 3331847
Vaccine. 1992;10(12):857-60
pubmed: 1455911
Pediatr Infect Dis J. 2008 Oct;27(10):881-5
pubmed: 18756185
Eur J Nutr. 2019 Aug;58(5):2029-2036
pubmed: 29936536
Vaccine. 2012 Jan 20;30(5):931-5
pubmed: 22142584
Am J Clin Nutr. 2016 Apr;103(4):1033-44
pubmed: 26864360
J Immunol. 2009 Apr 1;182(7):4296-305
pubmed: 19299729
Clin Microbiol Rev. 2019 Mar 13;32(2):
pubmed: 30867162
Vaccine. 2005 Jul 14;23(32):4158-66
pubmed: 15964484
Pediatrics. 1999 Feb;103(2):E14
pubmed: 9925860
JAMA. 1982 Apr 9;247(14):2012-5
pubmed: 7038174
J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):93-9
pubmed: 21694542
Indian J Gastroenterol. 2016 Jan;35(1):67-71
pubmed: 26876961
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
J Med Virol. 1993 Sep;41(1):30-4
pubmed: 8228934
PLoS One. 2021 Jul 1;16(7):e0253752
pubmed: 34197516
Clin Infect Dis. 2011 Jul 1;53(1):68-75
pubmed: 21653306
Nutrients. 2018 Mar 26;10(4):
pubmed: 29587438
Acta Paediatr Scand. 1985 Mar;74(2):213-8
pubmed: 3993367
Eur J Nutr. 2021 Feb;60(1):475-491
pubmed: 32390123
Dev Biol Stand. 1983;54:267-84
pubmed: 6228468
BMC Infect Dis. 2019 May 30;19(1):482
pubmed: 31146699
Front Endocrinol (Lausanne). 2018 May 31;9:246
pubmed: 29904370
Vaccine. 1999 Aug 6;17(23-24):3050-64
pubmed: 10462240
Clin Res Hepatol Gastroenterol. 2017 Feb;41(1):66-74
pubmed: 27459879
BMC Infect Dis. 2015 Mar 25;15:149
pubmed: 25884719
World J Gastroenterol. 2013 Feb 14;19(6):838-45
pubmed: 23430309
Pan Afr Med J. 2019 Mar 25;32:140
pubmed: 31303913

Auteurs

Nel Dabrowska-Leonik (N)

Immunology Department, Children's Memorial Health Institute, Warsaw, Poland.

Jolanta Sawicka-Powierza (J)

Department of Family Medicine, Medical University of Bialystok, Bialystok, Poland.

Ewa Bernatowska (E)

Immunology Department, Children's Memorial Health Institute, Warsaw, Poland.

Malgorzata Pac (M)

Immunology Department, Children's Memorial Health Institute, Warsaw, Poland.

Katarzyna Bernat-Sitarz (K)

Immunology Department, Children's Memorial Health Institute, Warsaw, Poland.

Edyta Heropolitanska-Pliszka (E)

Immunology Department, Children's Memorial Health Institute, Warsaw, Poland.

Barbara Pietrucha (B)

Immunology Department, Children's Memorial Health Institute, Warsaw, Poland.

Beata WolskaKusnierz (B)

Immunology Department, Children's Memorial Health Institute, Warsaw, Poland.

Aleksandra Lewandowicz-Uszynska (A)

Third Department and Clinic of Pediatrics, Immunology and Rheumatology of Developmental Age, Wroclaw Medical University, Wroclaw, Poland.

Bozena Mikoluc (B)

Department of Pediatrics, Rheumatology, Immunology and Metabolic Bone Diseases, Bialystok, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH